Open access · Peer reviewed · No APCs
Review ArticleJournal of Pharmacology and PharmacotherapeuticsVol. 5 | Issue 4 | 2014 | pp. 227–231Open access
Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
- 1,
- 2*,
- 3,
- 4
- 1 Department of Internal Medicine, The Commonwealth Medical College.
- 2 Department of Anesthesiology and Intensive Care Medicine, Gian Sagar Medical College, Patiala, Punjab, India.
- 3 Department of Internal Medicine, Wright Center, College.
- 4 Department of Emergency Medicine, Regional Hospital of Scranton, Scranton, Pennsylvania, USA.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Sukhminder Jit Singh Bajwa
Department of Anesthesiology and Intensive Care Medicine, Gian Sagar Medical College, Patiala, Punjab, India.
Email: sukhminder_bajwa2001@yahoo.com
Copyright: © 2014 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2014
- Received:
- Feb 22, 2014
- Accepted:
- Jan 16, 2014
How to cite
Sehgal, V., Bajwa, S. J. S., Sehgal, R., & Consalvo, J. A. (2014). Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon. Journal of Pharmacology and Pharmacotherapeutics, 5(4), 227–231. https://doi.org/10.4103/0976-500X.142428
Abstract
Canagliflozin is the first available oral inhibitor of sodium/glucose cotransporter 2 (SGLT2) in the market. At the outset it sounds excellent for the use in the elderly diabetic population, because of its minimal tendency to cause hypoglycemia. However, the clinician needs to exercise caution as it needs to be dosed renally. The clinician needs to be circumspect about potential drug interactions, especially when there is an underlying chronic kidney disease (CKD) and congestive heart failure (CHF). Also its use is best avoided in people who are predisposed to genital mycotic and urinary tract infections (UTI).
Keywords
Subject
Article metadata
| Title | Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon |
|---|---|
| Authors | Vishal Sehgal; Sukhminder Jit Singh Bajwa; Rinku Sehgal; John A Consalvo |
| Affiliations | Department of Internal Medicine, The Commonwealth Medical College.; Department of Anesthesiology and Intensive Care Medicine, Gian Sagar Medical College, Patiala, Punjab, India.; Department of Internal Medicine, Wright Center, College.; Department of Emergency Medicine, Regional Hospital of Scranton, Scranton, Pennsylvania, USA. |
| Corresponding author | sukhminder_bajwa2001@yahoo.com |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 5, Issue 4 (2014) |
Also in this issue
- Push, promote or educate…musings of a pharmacologist on drug promotionpp. 225–226
- Acetylated and propionated derivatives of swertiamarin have anti‑adipogenic effectspp. 232–238
- Oral carvedilol in escalating doses in the acute treatment of atrial fibrillationpp. 239–244
- The impact of irrational practices: A wake up callpp. 245–247
- Pharmacovigilance and adverse drug reaction reporting perspectives among interns and postgraduates of a teaching hospitalpp. 248–250
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026